Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of Dapirolizumab Pegol Treatment in Study Participants With Systemic Lupus Erythematosus

NCT04976322 is registered in ClinicalTrials.gov with UCB Biopharma SRL as lead sponsor.

NCT NCT04976322
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04976322 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of Dapirolizumab Pegol Treatment in Study Participants With Systemic Lupus Erythematosus
Lead sponsor
UCB Biopharma SRL
Phase
Phase 3
Overall status
Enrolling by invitation
Start date
July 27, 2021
Completion date
August 7, 2030
Enrollment
760 (estimated)
Sites
123

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus